Data Integrity : Key Lessons from the 2025 FDA Warning Letters Data Integrity Is a Leadership Problem, Not a Regional One: Lessons from 2025 FDA Warning Letters Executive Summary This report provides an evaluation of US FDA Warning Letters issued in calendar year 2025 that cite 21 CFR 211.68(b), focusing on automated and computerized systems used to generate, process, store, and report CGMP data
In the intervening time, it has dropped down to 36.4 percent, while diagnoses of diabetes are also stabilizing after rising for 15 years
Consistency matters more than any single session for achieving lasting outcomes
If a prescription is clinically appropriate, the provider writes one for the recommended treatment plan
PlexusDx offers Glutathione through its Longevity Protocols this article covers the mechanism, evidence, and genetic context that informs any decision to use it
Longer term For longer protocols, review metabolic, IGF-1, kidney, liver, and cardiovascular trends every 3 months with a clinician
